Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medicure ( (TSE:MPH) ) has provided an announcement.
Medicure Inc. has announced the acquisition of Gateway Medical Pharmacy through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., as part of its strategy to expand its direct-to-consumer pharmacy business. This acquisition is expected to enhance Medicure’s service offerings, support the growth of its products like ZYPITAMAG, and improve access and adherence for patients without incurring new debt or financing costs.
More about Medicure
Medicure Inc. is a pharmaceutical company focused on developing and commercializing healthcare products for patients and prescribers in the United States. The company primarily markets AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets through its U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, a pharmacy subsidiary that provides medication access across all 50 states, Washington D.C., and Puerto Rico with exceptional customer service and free home delivery.
YTD Price Performance: -13.37%
Average Trading Volume: 2,844
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$8.45M
For a thorough assessment of MPH stock, go to TipRanks’ Stock Analysis page.